Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response [Yahoo! Financ...
Benitec Biopharma Inc. (BNTC)
US:NASDAQ Investor Relations:
benitec.com/for-investors/investor-faqs
Company Research
Source: Yahoo! Finance
powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint • The first 4 patients enrolled into Cohort 1 have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the month-12 follow-up timepoint demonstrating durable response to BB-301 HAYWARD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that the first patient treated in Cohort 1 of the BB-301 Phase 1b/2a clinical study (NCT06185673) evaluating BB-301 for the treatment of dysp
Show less
Read more
Impact Snapshot
Event Time:
BNTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTC alerts
High impacting Benitec Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
BNTC
News
- Benitec Biopharma (NASDAQ:BNTC) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of ResponseGlobeNewswire
- Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) [Yahoo! Finance]Yahoo! Finance
- Benitec Biopharma (NASDAQ:BNTC) was given a new $32.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.MarketBeat
- Benitec Biopharma (NASDAQ:BNTC) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
BNTC
Earnings
- 11/14/25 - Beat
BNTC
Analyst Actions
- 11/4/25 - Citigroup Inc.
BNTC
Sec Filings
- 12/29/25 - Form 4
- 12/22/25 - Form 4
- 12/8/25 - Form SCHEDULE
- BNTC's page on the SEC website